Modulair (Montelukast)

Montelukast, the active ingredient in Modulair, is a leukotriene receptor antagonist presented as a tablet for oral use. It is indicated for asthma maintenance therapy, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children. GNH USA supplies Modulair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control chronic respiratory conditions. - Asthma maintenance therapy: reduces the frequency and severity of asthma symptoms and exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing, and itching caused by seasonal or perennial allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity, improving exercise tolerance.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often reported during treatment. - Abdominal pain: discomfort or cramps in the stomach area. - Nausea: feeling of queasiness without vomiting. - Dizziness: transient light‑headedness or balance disturbance.

Serious or Rare Side Effects: - Allergic reactions: including angioedema, urticaria, or anaphylaxis. - Neuropsychiatric events: mood changes, agitation, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should consider several safety aspects. - Liver function assessment: evaluate hepatic status, especially in patients with pre‑existing liver disease. - Neuropsychiatric monitoring: watch for mood alterations, depression, or suicidal ideation. - Severe asthma caution: do not substitute for rescue inhalers in acute attacks. - Hypersensitivity check: avoid use in individuals with known allergy to montelukast or any tablet excipients. - Store below 25°C: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines, requiring attention to potential changes in efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce montelukast plasma levels. - Phenobarbital: can lower drug exposure, compromising therapeutic effect.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline): may increase risk of neuropsychiatric side effects. - ACE inhibitors (e.g., lisinopril): combined use may raise the chance of angioedema. - Theophylline: additive bronchodilator effect may require dose adjustment.